Affiliations: [a] Director of Research, Alzheimer's Society, UK | [b] Professor of Age Related Diseases, King's College London, UK | [c] Head of Research, Alzheimer's Society, UK | [d] Senior Policy Officer, Alzheimer's Society, UK | Section of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Italy
Abstract: The drive for evidence based practice and cost-effective use of pharmacological therapies has advantages, but can also be problematic. These difficulties are particularly challenging in the context of long-term conditions, such as Alzheimer's disease. The complexity of the illness, the variable and complex pattern of service use and the difficulty of conducting long term clinical trials are extremely difficult to factor into a meaningful cost effectiveness model. In Alzheimer's disease, the additional impact on caregivers as well as the person with dementia should be considered. In the current article we give a brief overview of the clinical effectiveness of cholinesterase inhibitors for the treatment of Alzheimer's disease, discuss in detail the NICE appraisal of these treatments in the UK as an example of an attempt at a standardised evaluation of cost-effectiveness and discuss a proposed way forward to achieve a unified and consistent approach to the assessment of cost-effectiveness for anti-dementia therapies.
Keywords: Alzheimer's disease, cholinesterase inhibitors, cost-effectiveness, National Institute for Clinical Excellence (UK)
